Cautious Hold Rating for Arrowhead Pharmaceuticals Amid SRPT Developments and Market Uncertainties

Leerink Partners analyst Mani Foroohar has maintained their neutral stance on ARWR stock, giving a Hold rating on July 22.

Mani Foroohar has given his Hold rating due to a combination of factors affecting Arrowhead Pharmaceuticals. The recent developments regarding SRPT’s Elevidys, particularly the FDA’s recommendation to lift the voluntary hold for ambulatory patients, have been a positive signal for Arrowhead, as it led to the achievement of a significant milestone payment. However, the company’s stock remains volatile due to uncertainties surrounding SRPT’s future actions, such as potential equity monetization and the continuation of their partnership.
Despite the positive milestone achievement, there are ongoing concerns about the demand for Elevidys, safety issues, and the unpredictable nature of FDA decisions, which contribute to the uncertainty in Arrowhead’s market performance. These factors, combined with the potential for SRPT to impact Arrowhead’s financial stability, justify a cautious approach, leading to the Hold rating.

In another report released on July 22, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $14.50 price target.